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Chronic pain resulting from inflammatory and neuropathic disor-
ders causes considerable economic and social burden. Pharmaco-
logical therapies currently available for certain types of pain are
only partially effective and may cause severe adverse side effects.
The C5a anaphylatoxin acting on its cognate G protein-coupled
receptor (GPCR), C5aR, is a potent pronociceptive mediator in sev-
eral models of inflammatory and neuropathic pain. Although
there has long been interest in the identification of C5aR inhibitors,
their development has been complicated, as for many peptidomi-
metic drugs, mostly by poor drug-like properties. Herein, we report
the de novo design of a potent and selective C5aR noncompetitive
allosteric inhibitor, DF2593A, guided by the hypothesis that an
allosteric site, the “minor pocket,” previously characterized in CXC
chemokine receptors-1 and -2, is functionally conserved in the GPCR
class. In vitro, DF2593A potently inhibited C5a-induced migration of
human and rodent neutrophils. In vivo, oral administration of
DF2593A effectively reduced mechanical hyperalgesia in several
models of acute and chronic inflammatory and neuropathic pain,
without any apparent side effects. Mechanical hyperalgesia after
spared nerve injury was also reduced in C5aR−/− mice compared
with WT mice. Furthermore, treatment of C5aR−/− mice with
DF2593A did not produce any further antinociceptive effect com-
pared with C5aR−/− mice treated with vehicle. The successful me-
dicinal chemistry strategy confirms that a conserved minor pocket
is amenable for the rational design of selective inhibitors and the
pharmacological results support that the allosteric blockade of the
C5aR represents a highly promising therapeutic approach to control
chronic inflammatory and neuropathic pain.
C5a | inflammatory pain | neuropathic pain | allosteric antagonism | GPCR
Inflammatory and neuropathic pain are the most prevalent typesof pathological pain and represent important health problems.
Whereas inflammatory pain is one of the classic symptoms of the
inflammatory process, neuropathic pain arises from any of mul-
tiple nerve lesions or diseases, with symptoms including hyper-
algesia or allodynia (1, 2). Some of the most powerful painkillers,
including opioids and nonsteroidal anti-inflammatory drugs, are
only partially effective and prolonged exposure can cause un-
wanted effects (3, 4). As a result, there is continuous effort to
identify novel therapeutics for pain control with alternative bio-
logical mechanisms and that elicit fewer side effects.
Inflammatory mediators, including cytokines/chemokines, play
a critical role in the pathogenesis of inflammatory and neuropathic
pain (5, 6). Emerging evidences suggest that C5a, the anaphyla-
toxin produced by complement activation, has potent nociceptive
activity in several models of inflammatory and neuropathic pain
by interacting with its selective receptor C5aR (7, 8). C5aR belongs
to the class A subfamily of the seven-transmembrane (TM) G
protein-coupled receptors (GPCR) (9) and is widely expressed in
immune cells, including neutrophils (polymorphonuclear cells,
PMN), monocytes, microglia, and in nonimmune cells, including
neurons in the CNS and dorsal root ganglia (10, 11).
Evidence for a role of C5a in nociception sensitization has
been obtained in several models of inflammatory pain. For ex-
ample, C5a was produced at the inflammatory sites and elicited
mechanical hyperalgesia by activating the C5aR on infiltrated
PMN (7). Direct intraplantar injection of C5a in mice elicited
both heat and mechanical hyperalgesia by sensitizing primary
afferent C-nociceptors (12, 13). Local activation of C5aR has
been also implicated in the pathogenesis of postsurgical pain,
a model of postoperative pain (13). Finally, local administration
of PMX-53, a C5aR antagonist, attenuated mechanical hyper-
algesia induced by carrageenan, zymosan, or lipopolysaccharide
(7). In addition to the peripheral role of C5a/C5aR in in-
flammatory pain, up-regulated levels of C5 and C5aR have been
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found in spinal cord microglia in animals subjected to spared
nerve injury (SNI), a model of neuropathic pain (8). Indeed, C5-
null mice or the infusion of PMX-53 into the intrathecal space
reduced neuropathic pain hypersensitivity in the SNI model (8).
Collectively, these data suggest that a neuroimmune interaction
in the periphery and spinal cord through activation of the com-
plement cascade and the production of C5a contributes to the
genesis of both inflammatory and neuropathic pain.
As for other peptidergic GPCRs, the efforts to identify small
molecular weight C5aR antagonists have led to a limited number
of molecules, mostly lacking adequate potency and selectivity
(14). The most promising candidate so far described, PMX-53,
is a cyclic peptidomimetic antagonist designed to mimic the
C-terminal portion of C5a (15). Despite the encouraging results
obtained in preclinical studies, as for many peptide drugs, the
development of PMX-53 has been limited by its short half-life
and unfavorable bioavailability (16). In the present study, we
report the successful design of a nonpeptidic C5a allosteric small
molecular weight inhibitor driven by the structural information
on a minor pocket spanning between TM1, -2, -3, -6, and -7 that
is highly conserved across the GPCR family and that has been
recently proposed as a key motif for the intracellular activation
process. Reparixin was previously reported as a neutral allosteric
inhibitor of CXCR1 and CXCR2 that binds the TM in a region
that overlaps the minor pocket (17, 18). Combining the in-
formation from independent sources on structural and functional
features of allosteric sites in homologous chemokine receptors,
this paper intends to provide what is, to our knowledge, the first
example of de novo design of a new class of allosteric small
molecular weight inhibitors of a GPCR not belonging to the
chemokine receptor family, C5aR. The preclinical candidate,
DF2593A, is a potent and orally active C5a noncompetitive al-
losteric inhibitor with significant antinociceptive effects in a wide
range of inflammatory and neuropathic pain models.
Results
Binding Mode Characterization of DF2593A to C5aR.The human C5aR
(hC5aR) homology model was originally built using the human
CXCR1-reparixin complex (19) as a template, and subsequently
refined and compared with the C5aRmodel built starting from the
human C–C chemokine receptor type 5 (hCCR5) crystal structure
(PDB ID code 4MBS), in which CCR5 is bound with the mar-
keted HIV allosteric drug maraviroc (20, 21). Sequence identity
between hCCR5 and hC5aR is 21.3%, whereas sequence simi-
larity is 52.4%. Despite a low sequence identity, the key structural
features defining the minor pocket, the proline kink in TM2
and the water-mediated hydrogen bond network between the in-
tracellular segments of TM1, -2, -3, -6, and -7, is highly conserved
between chemokine receptors and C5aR. With the aim to develop
a specific site-binding model in C5aR, the pattern of polar inter-
actions involved in the anchorage of reparixin at CXCR1 was an-
alyzed in detail (19). Two of the three key residues of TM3, -6,
and -7 (Asn120 3.35, Tyr2586.51, and Glu2917.39) are fully con-
served (Asn1193.35 and Tyr2586.51) in C5aR (19, 22), and the
glutamic residue 7.39 (Val2867.39 in C5aR) is replaced by
Asp2827.35 one helix turn above (Table S1). Furthermore, as for
CXCR1, the minor pocket in C5aR is surrounded by a large
cluster of hydrophobic residues (Leu411.36, Phe932.61, Ile962.64,
and Leu2787.31) in the upper region of the TM layer (Fig. 1C).
Interestingly, Asp822.50, the crucial amino acid in the conserved
motif of TM2:L92%XXXD91% is also present in the binding cavity of
C5aR (23). The formation of a hydrogen bond between Asp822.50
and Asn2967.49 in TM7 is deemed crucial to activate C5aR (24).
Accordingly, the freezing of Asp822.50 in the inactive position with
DF2593A may prevent the crucial movement to switch C5aR to its
active state and it may represent a mechanistic explanation for the
inhibitory effect of DF2593A.
Based on these structural characteristics, a site-targeting library
was designed to identify a new class of allosteric C5aR modu-
lators. The phenylpropionic moiety was chosen as a privileged
scaffold to accommodate the shallow crevice between TM2, -3, -6,
and -7 and the trifluoromethyl group in the para position was
selected as promising substituent to establish a bidentate interaction
with Asn1193.35 and Asp822.50 bridging TM3 and TM2 associated
with the feature of the trifluoromethyl portion to engage additional
hydrophobic interactions (25, 26) (Table S2, compound 1). As we
were seeking for the key polar interactions with Asp2827.35 and
Tyr2586.51, a series of carboxamide and aminocarbonyl residues
bearing basic groups were synthesized. We found flexible tertiary
ω-aminoalkylamides (Table S2, compounds 2–3) and dual signifi-
cant inhibiting of C5a and CXCL8-induced chemotaxis, whereas the
insertion of conformationally rigid cyclic structures led to a full
selectivity versus the C5aR (Table S2, compounds 4–5). The ge-
ometry and the electronic status of the amido group were previously
demonstrated (25) to be key determinants to establish the polar
network in CXCR1/2 binding sites. Thus, the simple inversion of the
amide group in compound 2 was sufficient to loose affinity at
CXCR1/2, leading to the fully C5aR-selective isomer 6. The opti-
mization of the alkyl chain length and hydrophobicity (Table S2,
compounds 6–12) led to the selection of DF2593A (Table S2,
compound 9) as the most promising lead for further in vitro and
in vivo characterization (Fig. 1A). Extensive molecular dy-
namics and automatic docking runs on the C5aR/DF2593A
complex were performed to generate a reliable binding mode
hypothesis. Based on the refined model, DF2593A is able to bind
C5aR by two principal polar interaction patterns: (i) charge–
charge interaction between Asp2827.35and the charged nitrogen
of the piperidine ring of DF2593A, and (ii) a network of polar
interactions between the triflate and the couple Asn1193.35/
Asp822.50. Intriguingly, halogen-bond interactions are engaged
between fluorine atoms and carbonyl oxygen of both Asn1193.35
and Asp822.50.
The polar network is reinforced by the hydrogen bond between
the carbonyl group of Ile1163.32 and the amide moiety of DF2593A.
In addition, the phenyl ring of DF2593A is involved in a π–π
interaction with Tyr2907.43. As mentioned, the binding cavity is
also surrounded by hydrophobic residues, like Leu411.36,
Phe932.61, Ile962.64, Leu2787.31, and Val2867.39 (Fig. 1 B and C). It
has been observed that the Val286Ala7.39 mutant led to a mod-
erately inactive C5aR, supporting the hypothesis of a prominent
functional role of TM7 (27).
The allosteric nature of the C5aR minor pocket (17) and the
inhibitory activity of DF2593A were then investigated. Wild-type
receptor and seven Ala-scanning mutants of C5aR were tran-
siently transfected in L1.2 cells and tested for functionality. All
mutants but Asp2827.35 were nonsignificantly impaired in their
cell-surface expression (Fig. S1) and sustained effective cell mi-
gration in response to C5a (Fig. S2). Transfectants were then
tested in the C5a-induced chemotaxis assay in presence of
increasing concentrations of DF2593A. As shown in Fig. 1D,
the Asn1193.35Ala mutant is fully resistant to inhibition by
DF2593A, supporting the hypothesis that Asn1193.35 is a key res-
idue for ligand recognition. The dramatic effect of Tyr2586.51
Ala mutant was coherent with the ligand/receptor complex in
which the interaction established by the phenol group is es-
sential to orientate Asp2827.35 toward the piperidine nitrogen
of DF2593A. The Tyr2586.51 hydroxyl group could also act as a
hydrogen-bond donor versus the carbonyl group in the central
amide moiety of DF2593A. According to the proposed model,
also the bulky hydrophobic Leu411.36, Phe932.61, Ile962.64, and
Leu2787.31—even though not directly involved in ligand binding—
are structural and energetic determinants of the hydrophobic
domain governing the pattern of interactions within the hydro-
phobic cluster. The replacement of these residues with Ala
profoundly alters the shape and size of the pocket and coherently
significantly compromises DF2593A potency. Notably, sequence
alignment confirmed that key residues involved in the putative
DF2593A binding mode are well conserved in both rat and
mouse orthologs, supporting the potential of the candidate for
further preclinical pharmacology studies (Fig. S3).
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In Vitro Characterization of DF2593A. Pharmacological character-
ization showed that DF2593A did not inhibit spontaneous cell
migration per se and was >1,000-fold selective versus other che-
moattractants, including CXCL8 and CXCL1 (IC50 > 10 μM)
(Fig. 1E). DF2593A effectively inhibited C5a-induced human
PMN migration (IC50 = 5.0 nM) and cross-reacted with rat and
mouse orthologs (IC50 = 6.0 nM and IC50 = 1.0 nM, respectively)
(Fig. 1F). DF2593A (tested at 10 μM) was selective on a panel of
different GPCRs (Table S3) and ion channels (Table S4) and was
also completely inactive (percent inhibition = 10 ± 3; mean ± SD;
three experiments performed in duplicate) in a prostaglandin E2
(PGE2) production assay (28).
Binding experiments carried out on PMN membranes with
radiolabeled C5a showed that DF2593A did not compete with
binding of C5a. Pretreatment of PMN with DF2593A (1 μM) did
not change C5a affinity for C5aR (Kd = 1.8 ± 1 nM and 1.0 ±
0.4 nM in vehicle and DF2593A-treated groups, respectively; n = 3
per group). In addition, DF2593A did not affect the number of
C5aR molecules expressed on the cell membrane (127,000 ±
13,000 and 133,000 ± 21,000 binding sites per cell in vehicle and
DF2593A-treated groups, respectively) and did not alter C5a
binding to C5aR in displacement experiments (Fig. 1 G and H).
Pharmacokinetic Profile of DF2593A. The pharmacokinetics of
DF2593A was investigated in mouse after intravenous and oral
administration. Following oral administration (1 mg/kg) in mice,
DF2593A was well absorbed (F = 83%) with a Cmax of 0.1 μM, a
tmax of 1.2 h, and plasma samples harvested over a period of 12 h
generated free plasma drug concentrations in the range 0.016–
0.004 μM, about 4- to 16-fold greater than its in vitro IC50. For
Fig. 1. DF2593A is a selective noncompetitive allosteric inhibitor of C5aR. (A) Two-dimensional structure of DF2593A. (B) Two-dimensional representation of
DF2593A binding mode inside C5aR. Pink, green/blue and orange lines represent, respectively: charge–charge interaction, H-bond/halogen-bond interaction,
π–π and σ interactions. (C) Three-dimensional representation of DF2593A in the TM region of C5aR (violet). Interacting residues are shown using the following
color scheme: C (green), N (blue), O (red), S (yellow), F (cyan), and H (white); labeling is based on the Ballesteros–Weinstein numbering scheme. (D) Effect of
DF2593A on the C5a-induced migration of WT (●), L41A (○), F93A (□), I96A (▲), L278A (▼), N119A (▽), and Y258A (■) C5aR/L1.2 transfectants pre-
incubated with indicated DF2593A concentrations and then stimulated with 10 nM of C5a for 4 h. All mutants show a significant (P < 0.05) resistance to
DF2593A at all doses tested compared with WT C5aR transfectants. (E) Effect of DF2593A on the C5a-induced migration of human PMN preincubated for
15 min with indicated DF2593A concentrations and then stimulated with 10 nM C5a (●), 1 μM C5a-desarg (○), 10 nM CXCL1 (□), 1 nM CXCL8 (▲), 10 nM
CXCL12 (△), 30 nM CCL3 (▼), and 10 nM fMLP (▼) for 1 h. Significant inhibition was observed for C5a (at doses above 10−10 M) and C5a-desarg (at doses
above 10−9 M). (F) Effect of DF2593A on the C5a-induced migration of human (■), mouse (○) and rat (●) PMN preincubated with indicated DF2593A
concentrations and then stimulated with 10 nM C5a of corresponding origin. All leukocytes were significantly inhibited at doses above 10−10 M and were
equally sensitive. (G) Human PMN incubation with vehicle (●) or 1 μM of DF2593A (○) and then aliquots of 0.2 nM of [125I]-C5a and serial dilution of cold C5a
were added to 106 cells in 100 mL of binding medium. There was no significant difference between vehicle and DF2593A. (H) Human PMN were directly
exposed to vehicle or different concentrations of DF2593A (○) and then aliquots of 0.2 nM of [125I]-C5a and vehicle (DF2593A-treated PMN) or serial dilution
of unlabeled C5a (vehicle-treated PMN) (●) were added to 106 cells in 100 mL of binding medium. Significant difference were observed at doses above 10−9 M.
In D to F, data are expressed as percent of migrated cells observed in the absence of DF2593A (mean ± SD of three independent experiments). P < 0.01 versus
cell migration in the absence of DF2593A by Mann–Whitney U test. In G and H, data are reported as mean ± SD of three independent experiments.
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brain permeation studies, DF2593A was dosed intravenously at
10 mg/kg and the levels of DF2593A were 913 ng/g tissue and
673 ng/mL in brain and plasma, respectively, at 5 min postdose.
At 8 h postdose, significant levels of DF2593A were still present
in the brain (114 ng/g) and also in the plasma (56 ng/mL). The
brain-to-plasma ratios of DF2593A ranged from 1.36 (at 5 min
postdose) to 2.04 at 8 h postdose. In parallel, the distribution
coefficient, logBB, increased from 0.13 (at 5 min) to 0.3 (at 8 h),
suggesting good permeation of the molecule into the brain.
Antinociceptive Effects of DF2593A in Several Models of Inflammatory
Pain. C5a/C5aR interactions mediate carrageenan-induced me-
chanical hyperalgesia in rodents, suggesting it was a reasonable
model to evaluate the potential analgesic effect of DF2593A (7).
Corroborating this finding, carrageenan-induced inflammatory
hyperalgesia is reduced in C5aR−/− mice compared with WT mice
(Fig. S4). Consistent with its in vitro potency, oral administration of
DF2593A inhibited carrageenan-induced mechanical hyperalgesia
in a dose-dependent manner, but did not alter mechanical threshold
in naive mice (Fig. 2A). C5a-induced hyperalgesia was also blocked
by DF2593A, supporting the concept that DF2593A blocks hyper-
algesia by inhibiting the C5aR (Fig. 2B). Neither DF2593A nor
C5aR−/− deletion affected mechanical hyperalgesia induced by
PGE2 injected in the mice paws (Fig. 2C and Fig. S4). Furthermore,
DF2593A did not alter epinephrine-induced hyperalgesia in the
mice paws (Fig. 2C). In attempt to test the effect of DF2593A
against chemical nociception, a writhing test induced by zymosan
was studied (29). Oral treatment of mice with DF2593A signifi-
cantly reduced zymosan-induced writhing response (Fig. 2D).
DF2593A had no opioid-like affect in the hot-plate test and did
not cause any motor impairment that could have accounted for
the analgesic effects observed (Fig. 2 E and F). Treatment with
DF2593A or genetic deletion of C5aR (C5aR−/−mice) did not alter
carrageenan-induced PMN accumulation (Fig. S5), in agreement
with our previous findings (7).
The analgesic effect of DF2593A was then tested in the com-
plete Freund’s adjuvant (CFA)-induced chronic inflammatory
pain model. Oral pretreatment with DF2593A inhibited CFA-
induced mechanical hyperalgesia (Fig. 3A). Consistent with its
plasma levels, the effect of DF2593A was detected at least 6 h
after CFA injection, but not at 24 h (Fig. 3A). Next, we probed
whether the posttreatment with DF2593A could modify me-
chanical CFA-induced hyperalgesia and whether the analgesic
effect was maintained. As reported in Fig. 3 B and C, delayed
treatment with DF2593A (24 h after CFA injection) reduced
CFA-induced mechanical and thermal inflammatory hyper-
algesia. In a therapeutic setting, treatment with DF2593A starting
at 24 h after CFA injection and then twice a day for 1 wk reduced
mechanical hyperalgesia (Fig. 3D). Interestingly, the effect of
DF2593A was maintained and when DF2593A treatment was
stopped, mechanical hyperalgesia resumed to basal levels (Fig.
3D). There is evidence to suggest that C5a contributes to the
pathogenesis of rheumatoid arthritis, including arthritic pain (7,
30). Therefore, in the next step we evaluated the effect of
DF2593A in the genesis of articular hyperalgesia in two models
of arthritis in mice, antigen- and zymosan-induced arthritis. Oral
pretreatment with DF2593A effectively inhibited articular
hyperalgesia in both models (Fig. 3 E and F).
Antinociceptive Effects of DF2593A in the SNI Model of Neuropathic
Pain. Because activation of the complement system at the site
of nerve injury and in the spinal cord contributes to induction
and establishment of neuropathic pain (8, 31, 32), the effect of
DF2593A in the SNI-induced neuropathic pain model in mice
was evaluated. Oral treatment with DF2593A 7 d after surgery
clearly reduced mechanical hypersensitivity induced by SNI (Fig.
4A). The effects of DF2593A persisted at least 6 h after treatment
and, coherently with the pharmacokinetic profile, a progressive
loss of antinociceptive effect was observed after 24 h (Fig. 4A).
Confirming the involvement of C5aR in the genesis of neuropathic
pain, mechanical hypersensitivity 7 d after SNI was also reduced in
C5aR−/− mice compared with WT mice (Fig. 4B). Furthermore,
treatment of C5aR−/− mice with DF2593A did not produce any
further antinociceptive effect compared with C5aR−/− mice
treated with vehicle (Fig. 4B). The mechanical nociceptive
threshold of C5aR−/− naive mice did not differ from WT mice
(mechanical nociceptive threshold of naive WT mice: 7.2 ± 0.6 g
and naive C5aR−/− mice: 6.8 ± 0.1 g).
In a therapeutic setting, DF2593A was given twice a day from
day 7 to day 14 after surgery and mechanical hypersensitivity
measured 6 h after the first daily dose. As seen in Fig. 4C, the
effects of DF2593A were immediate and maintained over the ob-
servation period. Mechanical hypersensitivity returned to the same
level of SNI control group 2 d after the suspension of the DF2593A
treatment (Fig. 4C).
Discussion
This paper reports the molecular conception, synthesis, and
characterization of the preclinical candidate DF2593A that
shows potent and selective inhibitory effect on the C5a-induced
PMN migration and optimal pharmacokinetic and pharmaco-
logical profile in a panel of relevant inflammatory and neuro-
pathic pain experimental models.
In recent years, allosteric modulation of GPCRs has been
proposed as a promising new paradigm for the design of potent
and selective drugs with improved drug-like properties, finely
modulating the receptor function. There is emerging evidence
to suggest that, despite marked differences between the natural
ligands, GPCRs share common activation mechanisms involving
specific microswitches that regulate interhelical movements, which
offer unprecedented opportunities for the rational drug design of
Fig. 2. Antinociceptive effects of DF2593A on acute inflammatory pain
models. (A) Mice were treated orally with vehicle or DF2593A (0.5–2 mg/kg)
50 min before intraplantar injection of carrageenan (Cg, 100 μg per paw) or
vehicle (saline). (B) Mice were treated orally with vehicle (saline) or DF2593A
(1 mg/kg), 50 min before intraplantar injection of C5a (300 ng per paw). (C)
Mice were treated orally with vehicle (saline) or DF2593A (1 mg/kg), 50 min
before intraplantar injection of PGE2 (100 ng per paw) or epinephrine (300 ng
per paw). Mechanical hyperalgesia was evaluated 60 min after stimuli in-
jection. (D) Mice were treated orally with vehicle (saline) or DF2593A (1 mg/kg)
50 min before intraperitoneal injection of zymosan (1 mg per cavity). The
number of writhing responses induced by zymosan was evaluated for 20 min
n = 8. (E) The thermal nociceptive threshold in naive mice was evaluated be-
fore and at indicated time after DF2593A treatment (1 mg/kg) using a hot-
plate test. Morphine (8 mg/kg, s.c.) was used as a positive control. (F) Naive
mice were treated orally with vehicle or DF2593A (1 mg/kg) followed at in-
dicated times by evaluation in rota-rod test. Diazepam (7.5 mg/kg, s.c) was
used as a positive control. Data are shown as mean ± SEM (n = 6–8 per group).
*P < 0.05 compared with vehicle-treated animals.
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novel allosteric modulators. In this context, modeling and crystal-
lographic studies of the GPCRs have identified in the TM region of
GPCRs, a major pocket and a minor pocket, which has been
proposed as a “triggering domain” not involved in natural ligand
binding but crucial for the fine tuning of the global receptor acti-
vation process (17). Previous studies elucidated that reparixin, an
allosteric inhibitor of CXCL8 receptors, binds CXCR1 within the
minor pocket, locking the receptor in the inactive state by inter-
helical polar interactions with residues of TM1, -3, -6, and -7 (19).
Guided by the hypothesis that this minor pocket may represent
a functionally conserved site across the GPCR family, homology
modeling studies and molecular dynamics simulations of C5aR
were carried out. Despite the low overall identity between C5aR
and chemokine receptors, sequence analysis revealed that the
three key residues identified for reparixin and CXCR1 are con-
served in C5aR (22). Taking advantage of the structural diversity
of other residues surrounding the minor pocket in C5aR and
CXCR1, rational design was addressed by targeting a specific
pattern of interactions to retain full selectivity to C5aR. Extensive
site-directed mutagenesis studies in C5aR confirmed that this re-
gion is not directly involved in ligand receptor binding or critical
for receptor activation and function. This finding nicely fits with
the most accredited model of C5a/C5aR interaction (33), according
to which the flexible C-terminal of C5a is implicated in the
recognition of a domain distinct from the allosteric pocket and
delimited mainly by Arg2065.42, TM4, and the second extracellular
loop. Nevertheless, our studies clearly demonstrated that specific
ligands at this minor but conserved site are potent inhibitors of the
C5a-induced chemotaxis, acting as neutral noncompetitive allo-
steric inhibitors. Interestingly, as the key residues involved are
well conserved in both rat and mouse orthologs, the above results
pave the way for the rational design of allosteric C5aR inhibitors
with most favorable cross-species reactivity characteristics.
Previous studies have characterized the role of the C5a/C5aR
signaling in the genesis of inflammatory and neuropathic pain (7,
8). Neuropathic pain is an important and relatively common
clinical condition and available therapies are only partially effec-
tive. Among the events implicated in the genesis of neuropathic
pain, neuroimmune interactions, including spinal activation of
glial cells and the production of proinflammatory mediators, seem
to be important for pain amplification. It was shown that expres-
sion of common genes, including the complement system genes,
occurred in three different models of peripheral neuropathy (8).
These findings are in agreement with the inhibition of comple-
ment activation by the intrathecal administration of a soluble
human complement receptor type 1, which prevented the activa-
tion of C3 and C5 convertases and reduced mechanical allodynia
in various neuropathic pain models (31). Additionally, C6-deficient
rats still presented nerve injury-induced mechanical allodynia,
suggesting that the membrane attack complex assembling is not
necessary for the induction of neuropathic pain states (8). Ac-
cordingly, the nociceptive activity of the complement system
appears to be strongly dependent on the C5a/C5aR interaction.
Indeed, after nerve injury, expression of C5aR and C5 in the
microglial cells of the spinal cord increased, and C5-deficient
mice or intrathecal treatment with the classic antagonist PMX-53
ameliorated nerve injury-induced allodynia (8). Taken together,
this preclinical evidence strongly supports the hypothesis that
C5aR is an interesting target for neuropathic pain control.
The precise cellular site of action of DF2593A in the noci-
ceptive system is not fully understood. Considering the afore-
mentioned evidence of a role of C5a in the CNS, the efficacy of
DF2593A in the SNI model may arise in part from its perme-
ability to the blood–brain barrier. However, activation of the
complement system in the periphery, at the level of nerve injury
and dorsal root ganglia, could also contribute to the genesis of
neuropathic pain (32, 34). In the periphery, DF2593A could
disrupt the activation and the recruitment of leukocytes, thus
attenuating the direct sensitization of the primary nociceptive
neurons expressing C5aR (35). Importantly, DF2593A was ef-
fective even when given 1 wk after SNI, and nociceptive hyper-
sensitivity returned to basal values when the DF2593A treatment
was halted. These results clearly confirm the therapeutic po-
tential of DF2593A and show that continuous activation of the
C5aR is relevant for induction and maintenance of nociceptive
hypersensitivity in the SNI model.
Fig. 3. Effects of DF2593A on CFA-induced mechanical and thermal hyper-
algesia and arthritic nociception. (A) Mice were treated orally with vehicle or
DF2593A (1 mg/kg) 50 min before intraplantar injection of CFA (10 μL per
paw). (B) Mice were treated orally with vehicle or DF2593A (1 mg/kg) 24 h
after intraplantar injection of CFA (10 μL per paw). Mechanical or (C) thermal
nociceptive threshold was evaluated 2–24 h after DF2593A treatment. (D)
DF2593A (1 mg/kg) or vehicle was given at 24 h after CFA injection and then
twice a day until 7 d after CFA. Mechanical hyperalgesia was evaluated at 6 h
after the first daily dose of DF2593A. (E and F) Mice were pretreated orally
with vehicle (saline) or DF2593A (1 mg/kg) 50 min before intra-articular in-
jection of mBSA (30 μg per joint) in immunized mice or before intra-articular
injection of zymosan (150 μg per joint) in naive mice. Mechanical nociceptive
threshold was evaluated 6 h after stimuli injection. Data are shown as mean ±
SEM (n = 6 per group). *P < 0.05 compared with vehicle-treated animals.
Fig. 4. Antinociceptive effects of DF2593A in the
SNI model of neuropathic pain. (A) DF2593A (1 mg/kg)
or vehicle (saline) were given orally 7 d after SNI
surgery in mice. Mechanical hypersensitivity was
evaluated from 2 to 24 h after oral administration
of DF2593A. (B) Mechanical hypersensitivity was
evaluated 7 d after SNI surgery in WT and C5aR−/−
mice (time 0), followed by the treatment with ve-
hicle or DF2593A (1 mg/kg). Mechanical hypersen-
sitivity was then evaluated 2–24 h after DF2593A or
vehicle treatment. (C) DF2593A (1 mg/kg per dose)
or vehicle (saline) were given at day 7 and then
twice a day until 14 d after SNI. Mechanical hypersensitivity was evaluated at 6 h after the first daily dose of DF2593A during 1 wk. Data are shown as
mean ± SEM (n = 6 per group). *P < 0.05 compared with vehicle-treated animals.
Moriconi et al. PNAS | November 25, 2014 | vol. 111 | no. 47 | 16941
PH
A
RM
A
CO
LO
G
Y
In the inflammatory pain models, the actions of C5a appeared
to be sequential to PMN activation and are recruited into the
inflammatory site in response to chemokines and lipid mediators
(7). Recent evidence showed that C5aR is expressed in primary
nociceptive neurons and that C5a could directly sensitize these
fibers (12, 13). Our studies showed that DF2593A blocked
carrageenan and C5a-dependent mechanical hyperalgesia in vivo
without sedative or central opioid-like effects. Interestingly,
DF2593A was also effective in a model of chronic inflammatory
pain and in two models of inflammatory arthritic disease, even
when administered 24 h after the induction of inflammation,
sustaining the therapeutic potential of DF2593A and suggesting
that C5a is continuously produced and participates in the events
leading to maintenance of chronic inflammatory pain. On the
other hand, DF2593A did not affect mechanical hyperalgesia
induced by PGE2 or epinephrine, which directly cause sensiti-
zation of primary nociceptive neurons (6). Therefore, the anal-
gesic effects of DF2593A cannot be ascribed to a nonspecific
action and is related to its ability to block C5a/C5aR signaling,
presumably on both PMN and nociceptive neurons. Finally, it is
important to point out that the results obtained with C5aR−/−
mice strongly provide target validation/specificity for the effects
of DF2593A.
Our findings underline the functional relevance of the minor
pocket in GPCR that, although not directly involved in natural
ligand binding, cooperates with the fine-tuning of the receptor
activation process and represents an attractive structural de-
terminant for rational design of innovative therapeutic com-
pounds. Our pharmacological results not only provide further
support to the role of C5a/C5aR signaling in the generation and
maintenance of neuropathic pain, but also demonstrate that
DF2593A represents an innovative noncompetitive allosteric
drug candidate to control pain in multiple therapeutic indications.
Materials and Methods
See SI Materials and Methods for a full discussion of methods used.
Molecular Modeling. The TM domains of CXCR1, CXCR2, and C5aR were
identified by sequence alignments with rhodopsin structure by using the
MUSCLE software. The C5aR model was refined and compared with CCR5
(PDB ID code 4MBS) and further optimized by verifying the GPCR TM-
fingerprints alignment (20, 21). The C5aR TM bundle was assembled and
refined as described in SI Materials and Methods and the final C5aR structure
was used to dock DF2593A using LiGen.
Cells and Migration Assay. PMN and L1.2 cells migration was evaluated using
a 48-well microchemotaxis chamber, as previously described (19).
Mechanical Nociceptive Paw Test in Mice. Mechanical hyperalgesia was tested
in C57BL/6, BALB/C mice and in C5aR-deficient mice (C5aR−/−) using the
electronic von Frey test, as previously reported (6).
SNI-Induced Neuropathic Pain-Like Behavior. The SNI procedure comprised an
axotomy and ligation of the tibial and common peroneal nerves, leaving the
sural nerve intact (36).
Data Analyses and Statistics. For in vivo experiments, results are presented as
mean ± SEM. The differences among the groups were compared by ANOVA
(one-way) followed by Bonferroni’s post hoc test. The level of significance
was set at P < 0.05.
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SI Materials and Methods
Reagents. Compounds were routinely dissolved at the indicated
final concentrations in saline. All chemokines were from
PeproTech. All chemicals, cell culture reagents, CFA, zymosan, C5a,
and protease inhibitors were from Sigma. Dextran was from
Pharmacia LKB. Diff-Quik was from Harleco. Boyden chambers
and polycarbonate filter were from Neuroprobe. Transwell filters
were from Costar. Thioglycolate and lipopolysaccharide (from
Escherichia coli 055:B5) were from Difco. Pfx DNA polymerase
and pcDNA3 were from Invitrogen. Human C5a monoclonal
antibody was from BD PharMingen. Carrageenan was from FMC
Corporation. [125I]-C5a was from Amersham Pharmacia Biotech.
For PGE2 assay, the EIA kit (sensitivity 2.5 pg per well) was
purchased by Amersham.
Migration Assay.The procedure for obtaining informed consent of
the healthy donors from whom the peripheral blood was obtained
included an oral explanation by the physician in charge of the
investigation, or an authorized deputy, who illustrated the types of
samples that would be withdrawn, the procedures that would be
performed, the results that could be obtained, and their possible
consequences for the donor. The donors then provided written
informed consent approved by the S. Salvatore Hospital ethics
committee. PMN were obtained from buffy-coat of heparinized
human peripheral blood from adult healthy volunteers, as pre-
viously described (1). PMN were separated by dextran sedi-
mentation (1) and murine PMN obtained by injection of 3%
(vol/vol) thioglycollate into peritoneal cavities (1). Cell migration
of PMN was evaluated using a 48-well microchemotaxis chamber,
as previously described (1). Briefly, control medium (HBSS for
human and rodent PMN) or chemoattractant solution (10
nM fMLP, 1 nM CXCL8, 10 nM CXCL1, 10 nM C5a, 10 nM
CXCL12, 30 nM CCL3, 1 mM C5a des-Arg for hPMN, 10 nM
mC5a or rC5a for murine PMN) were seeded in the lower com-
partment of the chamber and cell suspensions were seeded in the
upper compartment. The migrated stained cells were counted by
microscope. L1.2 migration was evaluated using 5-μ pore size
Transwell filters, as previously described (2).
Generation of L1.2 Transfectants.C5aR cDNA coding sequence was
cloned in the pcDNA3.1 expression vector and used to generate
receptor mutants using the commercial Site-Directed Mutagen-
esis kit (Clontech). L1.2 cells were transiently transfected by
electroporation as previously described (2). After 36 h from
transfection, expression of C5a was assessed by flow cytometry
using an anti-human C5a monoclonal antibody.
Radioligand Binding Assay. [125I]-C5a (specific activity 2,200 Ci/mmol)
binding on human PMN was performed as previously described (3).
Nonspecific binding was determined by adding a 100-fold molar
excess of unlabeled C5a. Scatchard analysis and all calculations
were performed with the LIGAND program (4).
Macrophage Preparation and Lipopolysaccharide-Induced PGE2
Production. Peritoneal exudates cells were collected as previ-
ously described (5). Briefly, mononuclear cells were split into 96
wells, preincubated with DF2593A, and then stimulated with
lipopolysaccharide. The surnatants were harvested after 18 h and
PGE2 production was measured with an EIA kit.
Sequence Alignments and Molecular Modeling.All calculations were
performed using Dell PowerEdge R815 Rack Server 4 sockets/24
cores, 128GB RAM, under the Microsoft Windows Server 2008
R2 operating system. CXCR1, CXCR2, and C5aR sequence
alignments were obtained using the MUSCLE software (6) (Table
S1). Human, mouse and rat C5aR sequences were aligned using
MUSCLE software (Fig. S1). The C5aR homology model was built
using CCR5 crystal structure (PDB ID code 4MBS) as a template,
which is in bound-conformation with a small-molecule ligand (7,
8). Sequence identity between CCR5 and C5aR is 21.3%, and
sequence similarity (BLOSUM65) is 52.4%. CXCR1/2 vs. C5aR
sequences identity and similarity are, respectively, of 21.4% and
40.5% for CXCR1 and 26.2% and 49.9% for CXCR2. CCR5/
C5AR sequence alignment was manually adjusted to ensure
GPCRs TM-FPs alignment. The C5aR model was assembled and
submitted to energy minimization cycles to reduce intra- and in-
terhelical bumps between the amino acids side chains, by using the
CHARMm force field with Momany–Rone partial charges in
Discovery Studio 4.0 (Accelrys). The minimized model was sub-
mitted to MD runs (e = 1r) and heated to 300 K (heating time was
20 ps, equilibration time was 100 ps) with a production time of 1 ns
(harmonic constrains were applied to the backbone to allow re-
laxations to C5aR without loose the secondary structure). After the
MD, the last 100 ps of the run time were used to build an average
structure of C5aR. DF2593A was docked in the allosteric binding
cavity of C5aR for determining possible favorable ligand poses, by
using the LiGenDock (9, 10) docking program. The final poses
were clustered according to position and conformation, energy
ranked, and visually inspected. The best-ranked poses were refined
by in situ ligand minimization using Discovery Studio 4.0 with
CHARMm forcefield and flexible binding-site residue treatment.
Compound Synthesis. All reagents and solvents for the synthesis of
compounds 1–12 were purchased from Sigma-Aldrich or Lan-
caster and used without further purification. Optical rotations for
compounds 1–12 were measured on a Perkin-Elmer 241 polarim-
eter and the [α]D25 values are given in 10−1 deg·cm2·g−1. 1H-NMR
spectra were recorded on a Bruker AVANCE III 400 MHz
spectrometer. Melting points were determined using a Büchi
capillary melting point apparatus and are uncorrected. Reaction
courses and product mixtures were monitored by TLC on silica gel
(precoated F254 Macherey-Nagel plates); the spots were examined
with UV light and visualized with I2. The synthesis of compounds
1–3 (Table S2) was previously described (11, 12).
Compound 4: 4-{(2R)-1-[(1-methylpiperidin-4-yl)amino]-1-oxopropan-2-yl} phenyl
trifluoromethanesulfonate. To a solution of 4-phenyl trifluoromethane-
sulfonate acyl chloride derivatives (3.0 mmol) in CH2Cl2 (5 mL)
and triethylamine (3.5 mmol) (prepared as described in ref. 8),
1-methylpiperidin-4-amine (3.0 mmol) was added portion-wise.
The resulting solution was stirred for 3 h. After the disappearance
of the starting material, triethylamonium chloride salt was filtered
off and the solution was diluted with a saturated solution of
NaHCO3 (10 mL) and extracts with CH2Cl2 (3 × 10 mL). The col-
lected organic extracts were dried over Na2SO4, filtered, and
evaporated under vacuum to afford a crude 4-{(2R)-1-[(1-methyl-
piperidin-4-yl)amino]-1-oxopropan-2-yl}phenyl trifluoromethane-
sulfonate. The crudewas purified by flash chromatography (CHCl3/
CH3OH/cyclohexane/NH4OH 60:14:24:2) to afford 4-{(2R)-1-
[(1-methylpiperidin-4-yl)amino]-1-oxopropan-2-yl}phenyl trifluoro-
methanesulfonate (75% yield) as pale yellow oil. [α]D25 (c = 0.3,
CH3OH): +40.3;
1H-NMR (DMSO-d6) δ 7.40 (d, 2H, J = 7 Hz),
7.25 (d, 2H, J= 7Hz), 5.20 (bs, 1H,NH), 4.90 (q, 1H, J= 7Hz), 4.30
(m, 1H), 2.95(m, 2Hax), 2.30 (s, 3H), 2.12(m, 2Heq), 1.80(m, 4H),
1.45 (d, 3H, J = 7 Hz).
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Compound 5: 4-{(2R)-1-[(8-methyl-8-azabicyclo[3.2.1]octan-3-amine]-1-oxopropan-
2-yl}phenyl trifluoromethanesulfonate. To a solution of 4-phenyl trifluoro-
methanesulfonate acyl chloride derivatives (3.0 mmol) in CH2Cl2
(5 mL) and triethylamine (3.5 mmol) (prepared as described in
ref. 10), 8-methyl-8-azabicyclo[3.2.1]octan-3-amine (3.0 mmol)
was added portion-wise, the resulting solution was stirred for 3 h.
After the disappearance of the starting material, triethylamonium
chloride salt was filtered off and the solution was diluted with
a saturated solution of NaHCO3 (10 mL) and extracts with CH2Cl2
(3 × 10 mL). The collected organic extracts were dried over
Na2SO4, filtered, and evaporated under vacuum to afford
a crude 4-{(2R)-1-[(8-methyl-8-azabicyclo[3.2.1]octan-3-amine]-
1-oxopropan-2-yl}phenyl trifluoromethanesulfonate. The crude
was purified by flash chromatography (CHCl3/CH3OH/cyclohex-
ane/NH4OH 60:14:24:2) to afford 4-{(2R)-1-[(8-methyl-
8-azabicyclo[3.2.1]octan-3-amine]-1-oxopropan-2-yl}phenyl tri-
fluoromethanesulfonate, (68% yield) as yellow oil.[α]D25 (c = 0.3,
CH3OH): +29.3;
1H-NMR (DMSO-d6) δ 7.48 (d, 2H, J = 7 Hz),
7.25 (d, 2H, J = 7 Hz), 6.80 (bs, 1H, NH), 4.30 (m, 1H), 3.75
(m, 2Hax), 3.65 (q, 1H, J = 7 Hz), 2.75 (s, 3H), 2.60–1.90 (m, 8H),
1.45 (d, 3H, J = 7 Hz).
Compound 6: [4-[(1R)-1-(4-pyrrolidin-1-ylbutanoylamino)ethyl]phenyl] tri-
fluoromethanesulfonate. To a solution of ethyl 4-chlorobutyrate
(0.465 mL, 3.32 mmol) in DMF (2 mL), pyrrolidine (0.831 mL,
9.96 mmol), triethylamine (1.4 mL, 9.96 mmol), and a catalytic
amount of KI were added and the resulting solution was refluxed
overnight. After cooling at room temperature, the solution was
diluted with a saturated solution of NaHCO3 (10 mL) and ex-
tracts with Et2O (3 × 10 mL). The collected organic extracts
were dried over Na2SO4, filtered, and evaporated under vacuum
to give the ethyl 4-pyrrol-1-ylbutanoate as an oil (3 mmol), which
was used without further purification. To a solution of the ester
in dioxane (5 mL), few drops of 37% HCl were added and the
solution was refluxed overnight. After cooling at room temper-
ature, the solvent was evaporated under vacuum and the residue
was dried overnight in oven at 60 °C in vacuo. The crude
4-pyrrolidin-1-ylbutanoic acid was dissolved in CH3OH (4 mL)
and NaHCO3 (3 mmol) was added. After stirring for 2 h, the
precipitate was filtered off and the mother liquors concentrated
to afford the intermediate sodium 4-pyrrolidin-1-ylbutanoic
acid (55% yield) as a colorless oil.1H-NMR (DMSO-d6) d3.35
(m, 2H), 2.80 (m, 2H), 2.70 (m, 2H), 2.15 (m, 4H), 1.75 (m, 4H).
To a solution of sodium 4-pyrrolidin-1-ylbutanoic acid (0.381 g,
2.13 mmol) in dry CH2Cl2 (10 mL), 1,1′-carbonyldiimidazole
(0.645 g, 2.13 mmol) was added and the resulting solution was
left stirring at room temperature for 1 h. Triethylamine (0.597 mL,
4.25 mmol) and (1R)-1-[(4-trifluoromethanesulfonyloxy)phenyl]
ethylamine hydrochloride (0.65 g, 2.13 mmol) were added and the
resulting solution was left stirring at room temperature overnight.
A saturated solution of NaHCO3 (10 mL) was added and the two
phases separated. The organic one was washed with extracts with
a saturated solution of NaHCO3 (2 × 5 mL), dried over Na2SO4,
filtered, and evaporated under vacuum to give an oily residue. The
crude was purified by flash chromatography (CHCl3/CH3OH/cy-
clohexane/NH4OH 60:14:24:2) to afford [4-[(1R)-1-(4-pyrrolidin-
1-ylbutanoylamino)ethyl]phenyl] trifluoromethanesulfonate (75%
yield) as pale yellow oil. [α]D25 (c = 0.3, CH3OH): +40.3; 1H-NMR
(DMSO-d6) δ 8.15 (bs, 1H, NH), 7.35 (q, 4H, J = 7 Hz), 4.90
(q, 1H, J = 7 Hz), 3.35 (m, 2H), 2.90 (m, 2H), 2.80 (m, 3H), 2.25
(t, 2H, J = 3 Hz), 1.95 (m, 4H), 1.75 (m, 4H).
Compound 7: [4-[(1R)-1-(3-pyrrolidin-1-ylpropanoylamino)ethyl]phenyl] tri-
fluoromethanesulfonate. Following the same procedure described for
compound 6 and starting from pyrrolidine (0.325 mL, 3.9 mmol)
and ethyl 3-chloropropanoate (0.177 mL, 1.3 mmol), sodium
3-(pyrrolidin-1-yl)propanoate was obtained as a pale yellow solid
(62% yield).1H-NMR (DMSO-d6) d 3.35 (m, 2H), 2.80 (m, 2H),
2.70 (m, 4H), 1.75 (m, 4H). Compound 7 was then synthesized
following the procedure described for compound 6 and starting
from sodium 3-(pyrrolidin-1-yl)propanoate (0.231 g, 1.4 mmol)
and (1R)-1-[(4-trifluoromethanesulfonyloxy)phenyl]ethylamine
hydrochloride (0.458 g, 1.5 mmol) after workup and purification
by flash chromatography (CHCl3/CH3OH/cyclohexane/NH4OH
60:14:24:2). The title compound was obtained as yellow oil (55%
yield). [α]D25 (c = 0.3, CH3OH): +52.3; 1H-NMR (DMSO-d6)
δ 8.25 (bs, 1H, NH), 7.45 (q, 4H, J = 7 Hz), 5.01 (q, 1H, J = 7 Hz),
2.95 (m, 2H), 2.80 (m, 4H), 2.60 (m, 2H), 1.95 (m, 4H), 1.45
(d, 3H, J = 7 Hz).
Compound 8: [4-[(1R)-1-[3-(1-piperidyl)propanoylamino]ethyl]phenyl] tri-
fluoromethanesulfonate. According the same procedure described
for compound 6 and starting from piperidine (0.385 mL,
3.9 mmol) and ethyl 3-chloropropanoate (0.177 mL, 1.3 mmol),
sodium 3-(1-piperidyl)propanoic acid was obtained as a pale
yellow solid (78% yield).1H-NMR (DMSO-d6) d 3.35 (m, 2H),
2.80 (m, 2H), 2.15 (m, 2H), 1.95 (m, 2H), 1.75 (m, 6H). Com-
pound 8 was then synthesized following the same procedure
described for compound 6 and starting from (1R)-1-[(4-tri-
fluoromethanesulfonyloxy)phenyl]ethylamine hydrochloride
(0.335 g, 1.1 mmol) and sodium 3-(1-piperidyl)propanoic acid
(0.200 g, 1.12 mmol) to afford [4-[(1R)-1-[3-(1-piperidyl)prop-
anoylamino]ethyl]phenyl] trifluoromethanesulfonateas yellow
oil (63% yield). [α]D25 (c = 0.1, CH3OH): +48; 1H-NMR (CDCl3)
δ 7.60 (bs, 1H, NH), 7.40 (d, 2H, J = 7 Hz), 7.25 (d, 2H, J = 7 Hz),
5.15 (q, 1H, J = 7 Hz), 2.95 (m, 2H), 2.55 (m, 4H), 2.35 (t, 2H,
J = 3 Hz), 1.85–1.70 (m, 6H), 1.45 (d, 3H, J = 7 Hz).
Compound 9: N-[(1R)-1-(4-trifluoromethanesulfonyloxy)phenylethyl]-4-piperidin-
1-ylbutanamide. According the same procedure described for com-
pound 6 and starting from piperidine (0.385 mL, 3.9 mmol) and
ethyl 4-chlorobutyrate (0.182 mL, 1.3 mmol), sodium 4-(piperidin-
1-yl)butanoate was obtained as a white solid (76% yield). 1H-NMR
(DMSO-d6) d 3.35 (m, 2H), 2.80 (m, 2H), 2.70 (m, 2H), 2.15 (t, 2H,
J = 3 Hz), 1.95 (m, 2H), 1.75 (m, 6H). Compound 9 was then
obtained following the same procedure described for compound 6
and starting from (1R)-1-[(4-trifluoromethanesulfonyloxy)phenyl]
ethylamine hydrochloride (0.305 g, 1 mmol) and sodium 4-(piperidin-
1-yl)butanoate (0.193 g, 1 mmol). The crude was purified by flash
chromatography (CHCl3/CH3OH/cyclohexane/NH4OH 60:14:24:2)
to afford N-[(1R)-1-(4-trifluoromethanesulfonyloxy)phenylethyl]-
4-piperidin-1-ylbutanamide (75% yield) as pale yellow
oil. [α]D25 (c = 0.1, CH3OH): +40; 1H-NMR (CDCl3) δ 7.60
(bs, 1H, NH), 7.40 (d, 2H, J = 7 Hz), 7.25 (d, 2H, J = 7 Hz), 5.15
(q, 1H, J = 7 Hz), 2.95 (m, 2H), 2.55 (m, 6H), 2.35 (t, 2H, J = 3
Hz), 1.85–1.70 (m, 6H), 1.45 (d, 3H, J = 7 Hz).
Compound 10: (2R)-2-(3-benzoylphenyl)-N-hydroxypropanamide. In a 25-mL
round-bottomed flask equipped with a magnetic stirrer, a solution
of hydroxylamine hydrochloride (0.046 g, 0.66 mmol) and TEA
(121 μL, 0.88 mmol) in CHCl3 (2 mL) was stirred at room
temperature for 15 min.
Separately, a solution of (R) - Ketoprofen (0.056 g, 0.22 mmol)
in SOCl2 (3 mL) was refluxed for 3 h. After cooling at room
temperature, excess SOCl2 was distilled off under vacuum and
the crude acyl chloride diluted with CHCl3 (5 mL) and slowly
added into the hydroxylamine solution at T = 0 °C. After ice bath
removal, the reaction mixture was stirred for additional 2.5 h,
then was diluted in CHCl3 (30 mL), washed with 10% KHSO4
(3 × 10 mL), brine (3 × 10 mL), and dried over anhydrous
Na2SO4 to give a crude that, after purification by flash chro-
matography (CHCl3/CH3OH 98:2), afforded pure (2R)-2-(3-
benzoylphenyl)-N-hydroxypropanamide (0.040 g, 0.15 mmol) as
a white waxy solid (68%). [α]D25 (c = 0.34, CH3OH): −28;
1H-NMR (CDCl3) δ 10.5 (bs, 1H, NH), 7.81–7.78 (m, 3H), 7.70–
7.68 (m, 1H), 7.59–7.55 (m, 2H), 7.49–7.43 (m, 3H), 7.30 (bs, 1H,
OH), 3.85 (q, 1H, J = 7 Hz), 1.45 (d, 3H, J = 7 Hz).
Compound 11: (2R)-2-[3-(furan-2-ylcarbonyl)phenyl]-N-[4-(trifluoromethyl)-1,
3-thiazol-2-yl]propanamide. To a solution of (2R)-2-[3-(furan-2-ylcar-
bonyl)phenyl]propanoic acid (0.078 g, 0.32 mmol) in dry CH2Cl2
(5 mL), CDI (0.055 g, 0.34 mmol) was added and the resulting
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solution was stirred for 1 h at T = 0 °C. After ice-water bath
removal 4-(trifluoromethyl)-1,3-thiazol-2-amine (0.057 g,
0.34 mmol) and TEA (40 μL, 0.29 mmol) were added and the
resulting mixture was stirred at room temperature for 12 h. At
the complete disappearance of the starting material, a buffer
H3PO4/H2PO4
− solution (pH = 2.0, 5 mL) was added and the re-
action mixture was transferred into a separatory funnel. The two
phases were separated and the organic one washed with the
same buffer (3 × 5 mL), dried over Na2SO4, and evaporated
under vacuum to give a crude, which was purified by flash
chromatography (CHCl3/CH3OH 95:5). Pure (2R)-2-[3-(furan-
2-ylcarbonyl)phenyl]-N-[4-(trifluoromethyl)-1,3-thiazol-2 yl]
propanamide (0.091 g, 0.23 mmol) was isolated as a pale brown
solid (72%). [α]D25 (c = 0.26, CH3OH): −17.6; 1H-NMR
(CDCl3) δ 8.90 (bs, 1H, NH), 8.00–7.90 (m, 2H), 7.70 (s, 1H),
7.59–7.55 (m, 2H), 7.4 (s, 1H), 7.30–7.10 (m, 1H), 6.60 (s, 1H),
3.90 (q, 1H, J = 7 Hz), 1.75 (d, 3H, J = 7 Hz).
Compound 12: [4-[(1R)-1-[4-(1-methylpiperidin-1-ium-1-yl)butanoylamino]ethyl]
phenyl] trifluoromethanesulfonate iodide. To a solution of compound 9
(405 mg, 0.96 mmol) in 10 mL of dry THF, 0.598 mL (9.96 mmol)
of MeI were added and the solution was stirred at room tem-
perature overnight. The solvent was removed under vacuum to
give a solid that was triturated with 10 mL of n-hexane for
2 h. The solid was filtered and dried under vaccum at 50 °C
to afford [4-[(1R)-1-[4-(1-methylpiperidin-1-ium-1-yl)buta-
noylamino]ethyl]phenyl] trifluoromethanesulfonate iodide as
an orange solid. [α]D25 (c = 0.15, CH3OH): +27; 1H-NMR
(CDCl3) δ 7.58 (bs, 1H, NH), 7.75 (d, 2H, J = 7 Hz), 7.55 (d,
2H, J = 7 Hz), 4.5 (q, 1H, J = 7 Hz), 3.65 (m, 2H), 3.45–3.05
(m, 9H), 2.85 (t, 2H, J = 3 Hz), 1.95–1.90 (m, 6H), 1.45 (s, 3H,
J = 7 Hz).
In Vitro Selectivity of DF2593A. The effect of DF2593A (Tables S3
and S4) was evaluated on a panel of different GPCR (radioligand
binding assays) and on ion channels (calcium assay). For radioli-
gand binding, all of the reagents were purchased by PerkinElmer.
Assays were performed according to the manufacturer’s instruc-
tions. Sample radioactivity content was measured by a microplate
scintillation Beta-counter Top Count NXT. The ability of each
test article to act as an antagonist on three transient receptor
potential (TRP) channels was evaluated in a calcium assay.
For TRPV1 and TRPV4, experiments were performed with the
FLIPR Fluo-8 calcium Assay Kit according to the manufacturer’s
instructions. For TRPM8, experiments were performed with the
FLIPR Fluo-8 calcium Assay Kit according to the manufacturer’s
instructions (BD Bioquest).
Pharmacokinetics of DF2593A.Male C57BI/6J mice (Charles River)
were fed ad libitum and housed under controlled conditions with
a 12-h light-dark cycle. Procedures involving animals and their
care conformed to institutional guidelines that are in compliance
with national (D.L. n. 116, G.U. suppl. 40; February 18, 1992) and
international laws and policies [EEC Council Directive 86/609,
OJ L 358, 1; December 12, 1987; NIH Guide for the Care and Use
of Laboratory Animals (14)]. DF2593A was dosed in PBS for oral
(1 mg/kg) administration in fasted mice. Blood samples (n = 3
per time point) were harvested at different time points up to 12 h
after single dose administration. For brain permeation studies,
DF2593A was dosed intravenously at 10 mg/kg. Samples were
analyzed by LC/MS with appropriate standards. Pharmacokinetic
parameters were calculated using noncompartimental analysis
with WinNonlin 6.2 (Pharsight).
Animals. The behavioral experiments were performed on male
C57Bl6 mice (20–25 g) housed in the animal care facility of the
School of Medicine of Ribeirao Preto. Male C5a-receptor-deficient
mice (C5aR−/−) (C.129S4-C5ar1tm1cge/J) on a BALB/C back-
ground were purchased from The Jackson Laboratory. BALB/C
mice were used as control of C5aR−/−mice. All procedures were in
accordance with the guidelines of the International Association for
the Study of Pain on the use of animals in pain research.
Induction of Paw Inflammation. Mice received an intraplanta in-
jection of carrageenin (100 μg per paw) or CFA (10 μL) injected
subcutaneously into the plantar region of the hindpaw, as pre-
viously described (15, 16).
Mechanical Nociceptive Paw Test. Mechanical hyperalgesia was
tested in mice as previously reported (15). The test consisted of
evoking a hind paw flexion reflex with a hand-held force trans-
ducer adapted with a 0.5-mm2 polypropylene tip (Electronic von
Frey; IITC Life Science). The stimulus applied in between the
five distal footpads with a gradual increase in pressure was au-
tomatically discontinued and its intensity recorded when the paw
was withdrawn. The end point was characterized by the removal
of the paw in a clear flinch response after the paw withdrawal.
The results are expressed by the Δ withdrawal threshold (in
grams) that was calculated by subtracting the average of the last
three measurements after the treatments from the average of
three measurements before treatments.
Leukocyte Migration to the Paw Skin Tissue. The leukocyte migra-
tion to the subcutaneous plantar tissue of mice hind paw was
evaluated with the myeloperoxidase (MPO) kinetic-colorimetric
assay, as previously described (17). Samples of subcutaneous
plantar tissue were collected in 50 mM K2HPO4 buffer (pH 6.0)
containing 0.5% hexadecyltrimethylammonium bromide and
kept at −80 °C until use. Samples were homogenized using a
Polytron (PT3100), centrifuged at 16,100 × g for 4 min, and the
resulting supernatant assayed spectrophotometrically for MPO
activity determination at 450 nm (Spectra max), with three
readings in 1 min. The MPO activity of samples was compared
with a standard curve of neutrophils. Briefly, 10 μL of sample
was mixed with 200 μL of 50 mM phosphate buffer pH 6.0,
containing 0.167 mg/mL O-dianisidinedihydrochloride and 0.0005%
hydrogen peroxide.
Writhing Tests. The zymosan-induced writhing was performed as
previously described (18). Briefly, zymosan (1 mg/200 μL) was
injected into the peritoneal cavity of mice. These mice were placed
in a large glass cylinder and the intensity of nociceptive behavior
was quantified by counting the total number of writhes occurring
between 0 and 20 min after stimulus injection. The writhing re-
sponse consists of a contraction of the abdominal muscle together
with a stretching of hind limbs. The antinociceptive activity was
expressed as the writhing scores over the 20 min.
Hot-Plate Test. Mice were placed in a 10-cm-wide glass cylinder
on a hot plate (IITC Life Science) maintained at 55.0 °C. Two
control latencies at least 10 min apart were determined for each
mouse. The reaction time was scored when the animal jumped or
licked its paws. To minimize tissue damage, a maximum latency
(cut-off) was set at 30 s (18).
Measurement of Motor Performance. To discard possible non-
specific muscle relaxant or sedative effects of DF2593A, mice
motor performance was evaluated on the rota-rod test (18). The
apparatus consisted of a bar with a diameter of 2.5 cm, sub-
divided into six compartments by disks 25 cm in diameter (Ugo
Basile, Model 7600). The bar rotated at a constant speed of 22
rotations per minute. The animals were selected 24 h previously
by eliminating those mice that did not remain on the bar for two
consecutive periods of 120 s. Animals were treated orally with
vehicle or DF2593A (1 mg/kg). Diazepam (7.5 mg/kg, s.c.) was
used as a positive control. The cut-off time used was 120 s.
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Induction of Zymosan Joint Inflammation. Joint inflammation was
induced by administration of zymosan (150 μg) (Sigma) diluted in
0.9% saline into the right femur-tibial joint region of mice lightly
anesthetized. The volume administered was 10 μL via a 29-G
hypodermic needle inserted into the joint. Control animals
received a single intra-articular injection of the same volume of
sterile saline (19).
Antigen-Induced Arthritis. Mice were immunized as described
previously (20). Briefly, mice were sensitized with 500 μg of
methylated BSA (mBSA) in 0.2 mL of an emulsion containing
0.1 mL saline and 0.1 mL CFA (1 mg/mL of Mycobacterium tu-
berculosis) and given by subcutaneous injection on day 0. The
mice were boosted with the same preparation on day 7. Twenty-
one days after the initial injection, arthritis was induced in the
immunized animals by intra-articular injection of mBSA (30 μg
per cavity) dissolved in 10 μL of saline into the right femur-tibial
joint (20).
Articular Nociception. Articular nociception during zymosan and
antigen-induced arthritis was evaluated as previously described
(19, 20). For this test, a polypropylene tip probe with an area size
of 4.2 mm2 that was adapted to a hand-held force transducer,
instead of the standard tip probe (0.5 mm2), was applied on the
plantar surface of a hind paw to produce a tibio-tarsal flexion
movement. An increasing perpendicular force was applied to the
central area of the plantar surface of the hind paw to induce
a dorsal flexion of the tibio-tarsal joint, followed by paw with-
drawal. A tilted mirror below the grid provided a clear view of
the animal’s hind paw. The electronic pressure-meter apparatus
automatically recorded the intensity of the force applied when
the paw was withdrawn. The test was repeated until three sub-
sequently consistent measurements were obtained (i.e., the var-
iation among these measurements was less than 2 g). The
flexion-elicited withdrawal threshold is expressed in grams.
Thermal Nociceptive Test.The latency of paw withdrawal to radiant
heat stimuli was measured using a Plantar Ugo Basile apparatus
(Stoelting), as previously described (21). Mice can move freely in
this apparatus on an elevated glass surface with plastic boxes
above as the top cover. Mice were given a 1-h acclimation period
before testing until they became calm and motionless. A cali-
brated infrared light source of high intensity was applied per-
pendicular on the plantar surface of each mouse’s hind paw. The
end point was characterized by the removal of the paw followed
by clear flinching movements. Latency to paw withdrawal was
automatically recorded. Each hind paw was tested alternately
with an interval of 5 min for four trials.
SNI-Induced Neuropathic Pain-Like Behavior.Under isoflurane (2%)
anesthesia, the skin on the lateral surface of the thigh was incised
and a section made directly through the biceps femoris muscle
exposing the sciatic nerve and its three terminal branches: the
sural, common peroneal, and tibial nerves. The SNI procedure
comprised an axotomy and ligation of the tibial and common
peroneal nerves, leaving the sural nerve intact. The common
peroneal and the tibial nerves were tight-ligated with 5.0 silk and
sectioned distal to the ligation, removing 2 ± 4 mm of the distal
nerve stump. Muscle and skin were closed in two layers (22).
Data Analyses and Statistics. For in vivo experiments, results are
presented as mean ± SEM. The differences among the groups
were compared by ANOVA (one-way) and individual compar-
isons were subsequently made with Bonferroni’s post hoc test.
The level of significance was set at P < 0.05.
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Fig. S1. Expression levels of C5aR mutants. Cell surface expression of WT (black column) and indicated point mutants (white columns) of C5aR transiently
transfected in L1.2 cells. Results are mean ± SEM of three independent experiments. D282A-C5aR is the only mutant significantly impaired compared with WT
C5aR (P < 0.01).
Fig. S2. Chemotactic activity of C5aR mutants toward C5a. Chemotactic activity of increasing doses of C5a on the migration of wt (●), L41A (○), F93A (□),
I96A (▲), L278A (▼), N119A (▽), and Y258A (■) C5aR/L1.2 transfectants. Results are mean ± SEM of three independent experiments. A significant difference
(P < 0.05) was only observed for N119A-C5aR/L1.2 at 10 nM C5a.
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Fig. S3. Sequence alignment of human, mouse, and rat C5aR. Asn1203.35 and Tyr2586.51 are fully conservatively in the C5aR orthologs, whereas Asp2827.35 is
replaced by Asn7.35 in both the orthologs. Hydrophobic residues, Leu411.36 and Phe932.61 are also fully conserved in mouse and rat C5aR. Ile962.64 is conserved in
rat (Ile972.64) and is replaced by Val922.64 in mouse C5aR. Leu278 7.31 is replaced by a similar hydrophobic residue, Val2757.31 and Val2807.31 in mouse and rat,
respectively. Key residues of the allosteric pocket are shown in black boxes with Weinstein–Ballesteros annotation. Uniprot ID codes are provided.
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Fig. S4. Inflammatory hyperalgesia induced by carrageenan (Cg), but not by PGE2, is reduced in C5a-null mice. WT or C5aR
−/− mice received intraplantar
injection of Cg (100 μg per paw), PGE2 (100 ng per paw), or saline. At 3 h mechanical hyperalgesia was determined. Data are shown as mean ± SEM; *P < 0.05
when compared with wild type group; n = 6.
Fig. S5. Role of C5a in neutrophil migration during Cg-induced inflammation in mice paw. (A) Effect of DF2593A on the Cg-induced increase in paw MPO
activity. Mice were treated orally with vehicle (saline) or DF2593A (1 mg/kg) 50 min before intraplantar injection of Cg (100 μg per paw). MPO activity (number
of neutrophils 104/mg tissue) was evaluated in the plantar tissue 5 h after Cg injection. (B) WT and C5aR−/− mice receive an intraplantar injection of Cg (100 μg
per paw). MPO activity (number of neutrophils 104/mg tissue) was evaluated in the plantar tissue 3 h after Cg injection. Data are shown as mean ± SEM n = 6.
Table S1. Sequence alignment of key polar residues among
CXCR1/2 and C5aR
Two of the three key polar residues (Asn1203.35, Tyr2586.51, and Glu2917.39)
of CXCR1 are conservatively replaced (Asn1193.35 and Tyr2586.51) in C5aR,
whereas the lack of the glutamate in position 7.39 (Val2867.39 in C5aR) is
compensated by Asp2827.35. Uniprot ID codes are provided in parenthesis.
Amino acids are color coded by type: red, acidic residues; green, hydrophobic
aliphatic residues; blue, aromatic residues; violet, noncharged polar residues.
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Table S2. Effect of selected molecules on CXCL8-, CXCL1-, and C5a-induced human PMN chemotaxis
For CXCL8, CXCL1, and C5a, IC50 in nM (± SD).
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Table S3. Selectivity of DF2593A in a panel of different GPCRs
GPCR Ligand Mean ± SD
α1A-adrenoreceptor [125I]-HEAT 105.0 ± 5.7
α2A-adrenoreceptor [3H]-Rawolscine 88.5 ± 2.8
β1-adrenoreceptor [3H]-CGP12177 95.3 ± 14.2
β2-adrenoreceptor [3H]-CGP12177 97.3 ± 5.9
B1 [
3H]-(des-Arg10,Leu9)-Kallidin 95.5 ± 6.9
B2 Bradykinin 98.5 ± 6.0
CB1 [3H]-CP-55,940 92.5 ± 5.8
CB2 [3H]-CP-55,940 88.5 ± 13.4
D2 [3H]- Methylspiperone 91.7 ± 1.0
D3 [125I]-7-OH-PIPAT 85.4 ± 2.3
H1 [3H]-Pyrilamine 62.7 ± 0.7
H2 [125I]-Aminopotentidine 98.0 ± 9.31
M2* [3H]-N-methyl scopolamine 10.1 ± 0.8 (10 μM)
60.1 ± 1.1 (1 μM)
100.1 ± 5.1 (0.1 μM)
15.3 ± 0.7 (10 μM)
M3* [3H]-N-methyl scopolamine 55.1 ± 3.4 (1 μM)
95.4 ± 3.0 (0.1 μM)
NK1 [
125I]-Substance P 92.5 ± 0.7
μ [3H]-DAMGO 90.4 ± 3.1
κ [3H]-U69,593 88.4 ± 3.0
δ [3H]-Naltrindole 94.1 ± 14.9
NOP [3H]-Nociceptin 110.6 ± 2.9
5-HT1A [3H]-8-Hydroxy-DPAT 97.3 ± 17.8
Data are presented as mean (± SD, n = 3) of the percent of binding of
radioligand after the incubation with DF2593A at the single concentration
of 10 μM.
*The effect of DF2593A was evaluated at 10, 1 and 0.1 μM. DF2593A retains
about 1,000-fold of selectivity versus M2 and M3.
Table S4. Selectivity of DF2593A in a panel of different ion
channels
Ion channel Ligand IC50 (μM)
TRPM8 Icilin >10
TRPV1 Capsaicin >10
TRPV4 GSK1016790A >10
For TRPM8, TRPV1, and TRPV4 experiments, data are presented as IC50
values of three different experiments.
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